Statute Details
- Title: Health Products (Advertisement of Specified Health Products) Regulations 2016
- Act Code: HPA2007-S333-2016
- Type: Subsidiary Legislation (SL)
- Authorising Act: Health Products Act (Cap. 122D)
- Enacting Authority: Health Sciences Authority (with Minister for Health approval)
- Commencement: 1 November 2016
- Current Version: Current version as at 27 March 2026 (with key amendment: S 109/2021 effective 1 March 2021)
- Key Provisions (high level): Definitions (reg. 2); general advertisement requirements (reg. 3); matters excluded from advertising (reg. 4); substantiation of uniqueness/prominence (reg. 5); restrictions for specified diseases/conditions (reg. 6); prohibition for prescription-only medicines (reg. 7); pharmacy-only medicine advertisement requirements (reg. 8); unregistered product advertisement requirements (reg. 9); sales promotions (reg. 10); professional/scientific information advertising (reg. 11); reference/trade advertising (reg. 12); informational statements (reg. 13); sales promotions involving registered products (reg. 14); power to require copies (reg. 15)
- Schedules: First Schedule (relevant health professionals); Second Schedule (specified health products); Third Schedule (specified diseases or conditions)
What Is This Legislation About?
The Health Products (Advertisement of Specified Health Products) Regulations 2016 (“Advertisement Regulations”) regulate how “specified health products” may be advertised in Singapore. The central policy goal is consumer protection: advertisements must not mislead the public, must not encourage inappropriate self-diagnosis or treatment, and must not create unrealistic expectations about health outcomes.
In practical terms, the Regulations set out a compliance framework for advertisers, licensees, and other persons who publish or promote health products. They impose both “content” rules (what an advertisement must not say or imply) and “format/permission” rules (who may advertise certain categories of products, and under what conditions). They also address special advertising contexts such as sales promotions and professional or scientific information.
The Regulations operate alongside the Health Products Act (Cap. 122D). They are made under a specific enabling power (section 72 of the Health Products Act) and are designed to support the Act’s broader licensing, registration, and enforcement regime. For practitioners, the Regulations are best read as a detailed “advertising compliance code” that determines whether a particular advertisement is lawful and, if not, what corrective or enforcement action may follow.
What Are the Key Provisions?
1. Definitions and scope (reg. 2; reg. 3)
The Regulations define key terms that drive compliance. Notably, “specified health product” is defined by reference to the Second Schedule, and “therapeutic product” is defined by reference to the First Schedule classification. The Regulations also define “publish” broadly to include distributing, showing, displaying, exhibiting, issuing, disseminating or broadcasting by any form of communication. This breadth matters: it captures not only traditional media (print, TV, radio) but also online and promotional materials.
Regulation 3 links the Regulations to section 21(1) of the Health Products Act. It provides that an advertisement of a specified health product must (subject to modifications for certain categories of advertising) comply with the general rules in regulations 4, 5 and 6, and then satisfy additional category-specific requirements: regulations 7, 9 and 10 for most specified health products; and regulation 8 for therapeutic products only. This structure means that a single advertisement may need to be assessed against multiple layers of requirements.
2. Prohibited or excluded advertising content (reg. 4)
Regulation 4 is a “no-go” list. An advertisement must not be likely to cause harmful consumer behaviour or misinformation. The prohibitions include: (a) leading consumers to self-diagnose or inappropriately treat serious disease; (b) implying that advice from a registered pharmacist or qualified practitioner is unnecessary; (c) suggesting that medical consultation or surgical operation is not necessary if the product is used; and (d) encouraging inappropriate or excessive use.
Regulation 4 also targets misleading claims and fear-based marketing. Advertisements must not mislead about quality or efficacy (including by implication, emphasis, contrast or omission), must not compare or contrast with named competing products or brands, and must not exploit consumers’ lack of knowledge or use language/images likely to cause fear, alarm or distress about a disease or condition. Further, the Regulations prohibit “miracle” or guaranteed cure claims (infallible, unfailing, magical, miraculous; certain, guaranteed or sure cure), claims that there are no side effects, and claims likely to arouse unwarranted or unrealistic expectations.
Additional prohibitions address commercial inducements and endorsement: advertisements must not offer refunds or guarantee refunds, must not falsely claim government or public authority promotion/endorsement, must not be directed principally at persons below age 14, and must not contain any endorsement or recommendation by healthcare professionals (or by celebrities whose status is likely to encourage use). These restrictions are often the most litigated in practice because they relate to common marketing techniques.
3. Substantiation of uniqueness and prominence claims (reg. 5)
Where an advertisement contains statements asserting uniqueness or prominence—such as awards, certifications, or features differentiating the product—the statement must be substantiated by facts or evidence. This is a legal evidentiary requirement embedded in advertising law. Practically, advertisers should maintain documentary substantiation (e.g., award criteria, certification scope, test reports) that matches the precise claim made in the advertisement.
4. Restrictions for specified diseases/conditions and prescription-only medicines (regs. 6 and 7)
Regulation 6 restricts promoting specified health products for specified diseases or conditions. While the extract provided is truncated, the structure indicates that the Regulations impose additional limitations when the advertisement relates to particular diseases/conditions listed in the Third Schedule. For practitioners, this means that disease/condition references are not neutral: the compliance analysis must identify whether the advertisement is tied to a “specified disease or condition” and then apply the relevant restrictions.
Regulation 7 prohibits advertisement of prescription-only medicines. This is a categorical restriction: prescription-only medicines are not generally intended for direct consumer marketing. The practical consequence is that any attempt to market prescription-only products to the public—through websites, social media, flyers, or influencer content—may be unlawful unless it fits within a permitted exception (for example, professional or scientific information advertising, depending on the Regulations’ scope and modifications).
5. Pharmacy-only medicines and unregistered products (regs. 8 and 9)
Regulation 8 requires that an advertisement of a pharmacy-only medicine by a non-public sector person must prominently display a specified message or notice (the extract indicates a “prominently display” requirement). This ensures consumers are clearly informed that the product is pharmacy-only and must be obtained through appropriate channels.
Regulation 9 addresses advertisements of specified health products that are not registered under the Act. The extract indicates the Regulations impose requirements (likely including clear disclosure and restrictions) before such advertisements can be made. The key compliance point is that “registration status” is not a mere administrative detail; it affects whether and how the product may be advertised.
6. Sales promotions and other advertising formats (regs. 10–14)
Regulation 10 restricts sales promotions involving specified health products. The extract indicates a prohibition on certain promotional practices (the text is truncated), but the overall scheme is clear: sales promotions are treated as a high-risk advertising channel because they can intensify consumer pressure and encourage inappropriate use. Regulation 14 further addresses sales promotions involving registered specified health products, suggesting a more permissive or structured regime when registration requirements are met.
Regulations 11 to 13 address “professional or scientific information advertising,” “reference and trade advertisements,” and “informational statements.” These provisions recognise that not all health-related communications are intended to persuade consumers to buy or use a product. For example, trade catalogues, professional references, or purely informational statements may be treated differently, but still must comply with the Regulations’ overall safeguards and any modifications expressly provided.
7. Enforcement support: power to require copies (reg. 15)
Regulation 15 empowers the Authority to require, by written notice, any person who advertises (or causes advertisements to be advertised) to provide copies. This is a practical enforcement tool: it enables the Authority to review actual content, assess compliance, and take action without relying solely on summaries or screenshots.
How Is This Legislation Structured?
The Regulations are structured as a set of layered rules:
(1) Definitions (reg. 2) establish the meaning of key terms such as “publish,” “specified health product,” “therapeutic product,” “prescription-only medicine,” and “pharmacy-only medicine.”
(2) Core compliance framework (regs. 3–6) sets the general requirements for advertisements, including prohibited content (reg. 4), substantiation of uniqueness/prominence claims (reg. 5), and disease/condition-related restrictions (reg. 6).
(3) Category-specific rules (regs. 7–10) then apply based on product classification and advertising context: prescription-only prohibition (reg. 7), pharmacy-only display requirements (reg. 8), unregistered product requirements (reg. 9), and sales promotion restrictions (reg. 10).
(4) Special advertising categories (regs. 11–14) provide modifications or separate rules for professional/scientific advertising, reference/trade advertising, informational statements, and sales promotions involving registered products.
(5) Administrative/enforcement (reg. 15) provides the Authority’s power to require copies of advertisements.
The schedules then supply the “lookup tables” that determine which products and which diseases/conditions are relevant, and which health professionals are within the scope of endorsement-related restrictions.
Who Does This Legislation Apply To?
The Regulations apply to “advertisements” of “specified health products,” and the definition of “publish” is broad enough to capture many actors in the advertising chain. In practice, liability and compliance obligations can fall on advertisers, manufacturers/importers/wholesalers (including “licensees”), marketing agencies, and any person who causes advertisements to be published.
Several provisions expressly distinguish between “non-public sector persons” and public authorities. For example, the pharmacy-only medicine advertisement requirement (reg. 8) is framed for advertisements by non-public sector persons. The endorsement and endorsement-by-celebrity restrictions in reg. 4 also operate regardless of who is behind the advertisement, because they regulate the content and implications of the advertisement itself.
Why Is This Legislation Important?
For practitioners, these Regulations are important because they translate health-product regulatory policy into concrete advertising constraints. Many disputes in this area arise not from whether a product is registered, but from how it is marketed—particularly claims about efficacy, uniqueness, side effects, and disease outcomes. Regulation 4’s detailed prohibitions are designed to prevent precisely the kinds of marketing that can cause harm: self-treatment of serious disease, misleading “miracle cure” narratives, and fear-based messaging.
The substantiation requirement in regulation 5 is also significant. It shifts the compliance burden toward evidence-based marketing: if a claim is made, it must be supported. This is especially relevant for digital advertising where claims are often dynamic (e.g., “#1”, “award-winning”, “clinically proven”) and where substantiation must match the exact wording and context.
Enforcement is supported by the Authority’s power to require copies (reg. 15). This means that compliance reviews can be triggered by complaints, monitoring, or routine checks, and that advertisers should be prepared to produce the exact advertisement materials used in the market. Practically, legal teams should implement document retention and claim substantiation processes across marketing, e-commerce, and influencer campaigns.
Related Legislation
- Health Products Act (Cap. 122D)
- Medicines Act
- Medical Registration Act
- Dental Registration Act
- Midwives Act
Source Documents
This article provides an overview of the Health Products (Advertisement of Specified Health Products) Regulations 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.